FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
Amir Iravani, Medhat Osman, Alison M. Weppler, Roslyn Wallace, Anna Galligan, Arian Lasocki, Morgan Hunter, Tim Akhurst, Michael S. Hofman, Peter K. H. Lau, Damien Kee, George Au‐Yeung, Shahneen Sandhu, Rodney J. Hicks
Topics & Concepts
MedicineNivolumabInterquartile rangeMelanomaResponse Evaluation Criteria in Solid TumorsIpilimumabPET-CTNuclear medicineProgressive diseaseStandardized uptake valueInternal medicineAdverse effectPositron emission tomographyRadiologyGastroenterologyImmunotherapyCancerChemotherapyCancer researchCancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementRadiomics and Machine Learning in Medical Imaging